OUTFRONT Media Inc. Common Stock vs Relay Therapeutics Inc. Common Stock — how do they compare? OUTFRONT Media Inc. Common Stock trades at $29.55 (market cap $5.33B), while Relay Therapeutics Inc. Common Stock trades at $17.23 (market cap $3.81B). The key difference: OUTFRONT Media Inc. Common Stock is the larger of the two by market cap, and OUTFRONT Media Inc. Common Stock pays a 4.06% dividend while Relay Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold OUTFRONT Media Inc. Common Stock for 0 Days and Relay Therapeutics Inc. Common Stock for 5 Days on average.
| OUT | RLAY | |
|---|---|---|
Market Cap | $5.33B | $3.81B |
Volume | 1,197,618 | 1,706,150 |
Sector | Real Estate | Health |
52-Week High | $33.90 | $20.75 |
52-Week Low | $17.08 | $6.05 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $9.43B | $2.93B |
Dividend Yield | 4.06% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Relay Therapeutics (RLAY) trades at $17.36, down 3.45% today, with technical indicators showing bearish momentum. The company remains in clinical-stage development with negative profitability metrics, including a -2,763.64% net income margin and -$276.48M net loss for 2025. Recent Q2 2026 earnings missed expectations with a loss of $0.41 per share, though the company continues advancing its oncology pipeline with Phase 3 trials planned for 2027.
Despite unanimous analyst buy ratings and a $26.25 consensus price target representing 51% upside, RLAY faces significant execution risk as a pre-revenue biotech. The stock's bearish technical setup and persistent cash burn require careful risk management, though institutional accumulation and AI-driven drug discovery platform provide long-term potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
OUTFRONT Media Inc. is a US out-of-home media REIT that provides advertising space on billboard and transit displays across major markets in US and Canada.
Read more on OUT →Relay Therapeutics develops precision medicines for oncology and genetic diseases. Its drug discovery platform studies how protein motion affects drug targets to guide small-molecule medicine design.
Read more on RLAY →